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ABSTRACT

19

recreational purposes due to its antiemetic,

21

chronic use of cannabis can result in

23

known as cannabinoid hyperemesis syndrome.

16
18

Cannabis has long been used for medical and

20

analgesic, and mood effects. Ironically,

22

paradoxical effects, including a condition
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24

Patients with this syndrome are often seen

25

the ED with cyclic vomiting, nausea, and

27

treatment of cannabinoid hyperemesis

29

agent, medical management that includes

31

complications. Whereas common anti-emetic

33

lorazepam have been shown to be useful in

35

treatment of acute symptoms.

37

cannabis, cyclic vomiting, marijuana,

39

suggest 3 more keywords- DONE]]

26

epigastric pain. Although the definitive

28

syndrome is discontinuing the causative

30

rehydration is important to prevent

32

medications are ineffective, Haloperidol and

34

some studies to be effective in the

36

Keywords: cannabinoid hyperemesis syndrome,

38

antiemetic, side effects

[[AU: please

40
41
42

Cannabis, known for its psychoactive and

44

chemotherapy-induced nausea and vomiting, in

43

antiemetic effects, can be used to treat

45

addition to other medical conditions that
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46

may lead to cachexia, weight loss, and

48

effects, chronic cannabis use can cause

50

cannabis receptors. Cannabinoid hyperemesis

52

syndrome, was first identified in 2004.1 This

54

men and in studies is identified in patients

56

[[AU: please add reference] DONE – Please

58

and renumber following references.] Patient

60

acute gastroenteritis, intestinal

62

functional diseases of the bowel. These

64

making the diagnosis of CHS.

66

consider it in the differential diagnosis of

47

chronic pain. Despite these antiemetic

49

paradoxical effects from overstimulation of

51

syndrome (CHS), a type of cyclical vomiting

53

syndrome is most frequently seen in young

55

who report recreational use of cannabis.

57

use Reference #3 Simonetto for this citation

59

presentation may mimic acute pancreatitis,

61

obstruction, pseudo-obstruction, and other

63

medical conditions must be ruled out before

65
67

Clinicians who are aware of CHS can

patients with chronic nausea and vomiting.
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68

Early diagnosis of CHS can minimize long-

70

department (ED) visits and hospital

72

quick, effective treatment.

74

A GROWING PROBLEM

76

recreational substance for centuries. The

78

identify US societal health trends.2 Based on

80

use and health, marijuana remains the most

82

reference and statistics in this paragraph

84

NIH/NIDA reference associated with data in

86

National Institutes of Health, National

88

trend of cannabis use in the United States,

69

term morbidity, reduce costly emergency

71

admissions, and help clinicians provide

73
75

Cannabis has been a commonly used

77

CDC surveys the general population yearly to

79

data from the 2015 national study on drug

81

common illicit drug.2 [[AU: can this

83

be updated?] RESPONSE: Done, See 2018

85

the following sentence.] Additionally, the

87

Institute on Drug Abuse found an upward

89

with over 22.2 million US citizens age 12
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90

and older having reported using marijuana

92

survey.(NIH/NIDA)

94

cannabis is age 18 to 25 years. A study that

96

2002 and 2014, indicated that prevalence is

98

from the US national survey on drug use and

100

million women used marijuana in 2002. This

102

11.7 million women in 2014 *(Carliner et al,

104

CDC indicate that 10.6% of the male

106

or just those ages 18 to 25?]

108

female population surveyed use marijuana.2

110

reviewed 98 medical records of patients

91

within a month of taking the

93

highest number of individuals who use

95

investigated trends of marijuana use between

97

increasing among both men and women. Data

99

health show that 12.4 million men and 7.7

101

number increased to 18.4 million men and

103

2017). The most recent 2017 data from the

105

population surveyed [[AU: is that all males

107

Reworded for clarification] and 6.2% of the

109
111

The demographic with the

RESPONSE:

In 2012, a study conducted in Minnesota

diagnosed with CHS[[AU: please add
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112

reference] RESPONSE: Reference #3 Simonetto

114

the citation] with the goal of gaining a

116

CHS.³ Although the study corroborated

118

the CDC, clinically, CHS was seen to affect

120

of patients with CHS are male with an

122

deviation of +/- 9.9 years).3 Another

113

supports this statement. Please add this as

115

demographic perspective of patients with

117

findings from national studies completed by

119

many demographics. This study found that 67%

121

average age of 32.3 years (standard

123

important finding of the study was that 68%

125

of using cannabis for an average of 2 years

127

59% of the patients used cannabis daily, and

124

of patients diagnosed with CHS had a history

126

before the onset of symptoms. Additionally,

128

95% used it at least once per week.3

130

popularity among adolescents and younger

132

names such as “K2” and “spice”. [[AU: please

129

More recent trends show an increase in

131

adults of synthetic cannabis, with street

133

add reference] RESPONSE: Done, please use
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134

reference #4 Ukaigwe as the citation to

135

support this statement]4 Although surveys

137

users over its synthetic derivative, users

139

undetectable in routine drug testing.4 Few

136

show that natural cannabis is preferred by

138

are resorting to synthetics because they are

140

studies have investigated the relationship

142

a recent case report identified a patient

144

CHS.4 CHS remains an important diagnosis to

146

drug screen despite clinical suspicion.

148

toward the national legalization of cannabis

150

once-rare syndrome has become increasingly

152

constitution to allow medical cannabis use.

154

of Columbia, Maine, Massachusetts, Michigan,

141

between synthetic cannabis and CHS, although

143

with a history of chronic “spice” use and

145

consider in patients who test negative on a

147

With current political trends leaning

149

for medicinal and recreational use, this

151

prevalent. In 2000, Colorado amended its

153

Alaska, California, Colorado, the District

155

Nevada, Oregon, Vermont, and Washington
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156

state have legalized recreational use of

158

it for medical use only. As of 2018, 33

160

restrictions for medical use and 11 having

162

use.(Governing, 2018) [[AU: 2018 stats, from

164

justice/state-marijuana-laws-map-medical-

166

2018 stats and included the above source

168

existing references.] Few studies have shown

170

changes, however a single study in Colorado

172

seen in the ED since the legalization of

157

cannabis, and 23 other states have legalized

159

states have legalized marijuana, some with

161

legalized it for recreational

163

www.governing.com/gov-data/safety-

165

recreational.html] RESPONSE: Added these

167

(Governing) as a reference at the end of the

169

an increase of CHS secondary to legalization

171

showed that the number of patients with CHS

173

cannabis has doubled.5

175

published in 2018 indicating an increased

177

vomiting. This study reflects a time period

174
176

More recently, a study using ICD codes was

number of ED visits for cannabis-associated

Document18 07/24/19- 9

178

from 2006 to 2013 during which an increased

180

recreational use of marijuana. Marijuana-

182

2,915 of 1,369,942 (.2%) total cases of

184

(0.9%)of vomiting cases seen in the ED in

179

number of states legalized medical and

181

related cases of vomiting increased from

183

vomiting in 2006 to 17,904 of 1,922,448

185

2013. (Bollom)

187

PHYSIOLOGY

189

been identified in the autonomic and central

191

receptors also can be found in the spleen,

193

liver, uterus, bladder, and vas deferens.

195

delta-9-tetrahydrocannabinol (THC), a

197

psychoactive effects associated with

199

consciousness, relaxation, euphoria,

186
188

Two cannabinoid receptors (CB1 and CB2) have

190

nervous systems of humans and animals. These

192

stomach, small and large intestine, heart,

194

The interaction between CB1 receptors and

196

chemical component of cannabis, triggers the

198

cannabis use. These effects include altered
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200

perceptual disturbances, cognitive

202

disturbances. THC potentiates antiemetic

204

located at the vomiting center in the

201

impairment, and intensified sensory

203

effects by interacting with CB1 receptors

205

medulla.

207

SIGNS AND SYMPTOMS

209

with CHS are recurrent episodes of nausea,

211

hot-water bathing. Because patients cannot

213

weight and become dehydrated. The specific

215

CHS has not been identified; however,

217

explain the symptoms.

219

simply be a result of metabolites from

221

the mechanism that most likely explains CHS

206
208

The classic signs and symptoms associated

210

vomiting, abdominal pain, and compulsive

212

hold food or liquid down, they may lose

214

mechanism of action of THC in patients with

216

physiologic concepts have been proposed to

218

Nausea and vomiting These symptoms could

220

impure or contaminated cannabis. However,

Document18 07/24/19- 11

222

is that THC is a lipophilic molecule that

224

fat) and is secreted over its extended half-

226

hyperstimulation of the CB1 and CB2

228

desensitization of the CB1 and CB2 receptors

230

excessive exposure to THC, antiemetic

232

reducing gut motility and inducing emesis

234

variations of metabolic enzymes in the liver

236

the pro-emetic effects of cannabis after

238

offers a potential explanation as to why not

240

experiences CHS.

242

receptors in the gut may be the cause of

223

accumulates in body fat (including cerebral

225

life. This chronic exposure leads to

227

receptors.1 Down-regulation and

229

increases the bioavailability of THC.6 With

231

effects on the brainstem are overridden,

233

due to gastroparesis.6 Additionally, genetic

235

that may predispose a patient to experience

237

chronic cannabis use.1 This variability

239

every patients who uses cannabis chronically

241
243

Abdominal pain Hyperstimulation of CB

abdominal pain associated with CHS;
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244

hyperstimulation of CB1 and CB2 causes

246

volume, potentially leading to pain.3

248

of abdominal pain. Studies show that most

250

periumbilical pain.3

252

is a learned behavior intended to relieve

254

report this behavior during their initial

256

the nausea, cyclic vomiting, and abdominal

258

hypothalamus, the brain’s center for

260

and hot showers may counteract chronic

262

use[[AU: stimulation caused by cannabis

264

clarification.].7 Hot water may also

245

splanchnic dilation and increases blood

247

However, not all patients with CHS complain

249

patients experience epigastric or

251

Compulsive hot showers Compulsive bathing

253

symptoms of CHS; patients may or may not

255

history. Why hot showers appear to relieve

257

pain of CHS is unknown. However, the

259

thermoregulation, contains CB1 receptors,

261

hypothalamus stimulation caused by cannabis

263

use?] RESPONSE: Yes. Sentence modified for

265

stimulate CB1-mediated vasodilation,
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266

redistributing blood flow from the

268

resulting in cutaneous steal syndrome and

267

splanchnic circulation to the skin,

269

temporarily relieving symptoms.

271

98 patients with CHS revealed that symptoms

273

symptoms included diaphoresis, bloating, and

275

with specific foods.3

277

HISTORY AND PHYSICAL EXAMINATION

279

tenderness on palpation, patients typically

281

clinical diagnosis, and an accurate and

270
272
274
276

Timing and associated symptoms A survey of

typically started in the morning.3 Associated

weight loss.3 Symptoms were not associated

278

Other than abdominal discomfort or

280

have a normal physical examination. CHS is a

282

thorough patient history is essential.

284

phases. Clinicians should maintain a high

286

with this sequence of events:

283
285

The course of an episode of CHS occurs in

suspicion of CHS when a patient presents

Document18 07/24/19- 14

287

Pre-emetic phase Also called the prodromal

288

phase, this phase can last for months to

290

abdominal discomfort, anxiety, agitation,

292

Patients also may exhibit autonomic symptoms

294

During this phase, normal eating habits are

296

cannabis because of its commonly known

298

may then increase their cannabis use to

300

realizing that it could escalate the course

289

years and begins with intermittent diffuse

291

morning nausea, and fear of vomiting.

293

of sweating, flushing, and increased thirst.

295

maintained and patients continue to use

297

antiemetic and antinausea effects. Patients

299

self-medicate and to treat their nausea, not

301

of the episode.

303

typically lasts 24-48 hours,(Galli et al,

305

nausea and cyclic vomiting. Patients begin

307

and may experience mild abdominal pain.

302

Hyperemetic phase In this phase, which

304

2011) patients experience incapacitating

306

vomiting profusely up to five times per hour

308

Patients begin to lose weight due to the

Document18 07/24/19- 15

309

inability to hold down food. In the clinical

311

dehydration but are hemodynamically stable.

313

may report taking numerous hot showers

315

symptoms.

317

stops using cannabis and is placed on

319

intravenous (IV) fluids, and electrolyte

321

normal diet. Patients regain their weight

323

Complete resolution of symptoms can take up

310

setting, these patients usually present with

312

Additionally, during this phase, patients

314

throughout the day to help relieve their

316

Recovery phase In this phase, a patient

318

conservative treatment such as bowel rest,

320

replenishment, and is slowly advanced to a

322

and their bathing habits revert to normal.

324

to 1 month.

326

DIAGNOSTIC TESTS

328

can be extensive and expensive. With an

330

rule out medical emergencies is warranted.

325
327

The workup for chronic nausea and vomiting

329

initial episode of CHS, a thorough workup to

Document18 07/24/19- 16

331

Initial laboratory tests should include a

333

blood glucose, basic metabolic panel,

335

urinary toxicology screen, and abdominal

337

test is critical to rule out hyperemesis

332

complete blood cell count and differential,

334

pancreatic and hepatic enzymes, urinalysis,

336

radiographs. In female patients, a pregnancy

338

gravidarum.

340

DIFFERENTIAL DIAGNOSIS

342

in obtaining a thorough history from

344

Questions about cannabis use are essential.

346

learned behavior, patients may or may not

339
341

An algorithm is available to aid clinicians

343

patients who may have CHS (Figure 1).8

345

With compulsive bathing being considered a

347

exhibit this behavior.

349

diagnoses that closely resemble CHS:

351

diagnosis in patients without a history of

348
350
352

Providers should be mindful of two

Cyclic vomiting syndrome Consider this

chronic cannabis use. Patients with cyclic

Document18 07/24/19- 17

353

vomiting syndrome typically present with

355

vomiting; psychologic stressors are

357

from CHS. The family history usually is

359

typically respond well to migraine abortive

361

patients with CHS generally do not respond

354

migraine headaches, abdominal pain, and

356

pertinent in distinguishing this syndrome

358

positive for migraine headaches. Patients

360

and or preventive relief medications;

362

to these medications.

364

is associated with a history of vomiting

366

with no obvious organic disease. It is

368

disorders such as depression or obsessive-

370

psychogenic vomiting is hyperemesis with

372

organic gastrointestinal dysfunction. In

374

emotional issue with behavioral therapy,

363

Psychogenic vomiting This condition usually

365

caused by psychologic stimuli in a patient

367

common in patients with psychologic

369

compulsive disorder. The presentation of

371

emotional triggers but without an identified

373

these patients, treating the underlying

Document18 07/24/19- 18

375

antidepressants, and supportive

377

hyperemetic symptoms.

379

COMPLICATIONS

381

misdiagnosed. For this reason, data on

383

syndrome are limited. Clinicians should be

385

induced by natural and synthetic cannabis.

387

risk of becoming hypovolemic, leading to

389

injury or Mallory-Weiss tear.

391

acute prerenal failure due to volume

393

acute kidney injury and rhabdomyolysis. One

395

presented to the ED with complications of

376
378

psychotherapy causes resolution of the

380

CHS is commonly underdiagnosed and

382

medical complications related to this

384

mindful of potential complications of CHS

386

With intractable vomiting, patients are at

388

acute kidney injury and potential esophageal

390

Patients with CHS are at risk of developing

392

depletion. Severe dehydration can lead to

394

case study described a 25-year-old man who

396

CHS.9 He had an elevated blood urea nitrogen
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397

to creatinine ratio of 24:3.21 that

399

Another case study described a patient with

401

researchers determined that this patient

403

hyperemesis-induced electrolyte

405

cannabis.10

407

emesis are at risk of developing Mallory-

409

year-old woman who was pregnant at the time

411

vomiting with hematemesis, and abdominal

413

gravidarum. It was not until the patient did

415

had returned to the ED on multiple occasions

417

finally inquired about drug use [[AU: and

398

normalized after 24 hours of IV rehydration.9

400

CHS secondary to synthetic cannabis use. The

402

developed rhabdomyolysis because of either

404

abnormalities or contamination of the

406

Patients who exhibit constant or forceful

408

Weiss tears. A case study investigated a 28-

410

of presentation and complained of nausea,

412

pain. Clinicians assumed she had hyperemesis

414

not respond to antiemetic medications and

416

for the same symptoms, that clinicians

418

found out that she was used cannabis and was
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419

diagnosed her with CHS? what about the

421

too?] RESPONSE: DONE – YES, Thank you. Info

423

marijuana. Upon discharge she was diagnosed

425

symptoms resolved after cessation of

427

that healthcare providers should inquire

429

age, sex, or childbearing state.

431

TREATMENT

433

fluids, is the first step in managing CHS.

435

hyperemesis causes patients to become

437

electrolytes can prevent acute prerenal

439

if well tolerated, is the preferred route of

420

Mallory-Weiss tears? did she have those,

422

added below] and confirmed chronic use of

424

with Mallory-Weiss tears and CHS. Her

426

marijuana.11 This supports the recommendation

428
430

about drug use regardless of the patient’s

432

Rehydration, either orally or using IV

434

Because excessive fluid loss from

436

hypovolemic, replenishing essential

438

injury and renal failure. Oral rehydration,

440

rehydration. If the patient is unable to

Document18 07/24/19- 21

441

tolerate oral intake, IV infusion of 0.9%

442

sodium chloride solution or 5% to 10%

444

adequate treatment in many cases. Because

446

endoscopy to manifest gastritis and

448

inhibitor is indicated for healing.(Galli et

450

patients. Cessation of cannabis use

452

the patient completely stops using cannabis,

454

participate in a 12-step program or support

456

study conducted by the National Institute on

458

the benefits of N-acetylcysteine (NAC), an

460

cannabis cessation.12 They found it effective

462

subjects participating in the study.12 NAC is

443

dextrose, in addition to IV potassium, is

445

patients with CHS have been shown on

447

esophagitis, treatment with a proton pump

449

al, 2011) Bowel rest is essential in all

451

ultimately cures CHS. Studies show that once

453

symptoms resolve. Recommend that the patient

455

group as a means of recovery. A double-blind

457

Drug Abuse Clinical Trials Network examined

459

antidote for acetaminophen overdose, in

461

in promoting abstinence from cannabis in the

Document18 07/24/19- 22

463

easily accessible, available over-the-

464

counter, and is fairly inexpensive.

466

antiemetic medications such as ondansetron,

468

promethazine are ineffective for active

470

Haloperidol, a medication typically

472

be effective in patients with CHS.13 The

465

It is important to note that traditional

467

metoclopramide, prochlorperazine, and

469

symptom relief in patients with CHS.

471

indicated for psychosis and agitation, may

473

mechanism of action for haloperidol’s

475

unknown; however, effectiveness may be

477

dopamine D2 and CB1 receptors.13 Haloperidol

479

should be weighed against the benefits in

481

haloperidol in acute episodes can

483

in the ED, and reduce the rate of hospital

474

antiemetic effects in these patients is

476

attributed to complex interactions between

478

is a category C medication and its risks

480

pregnant patients. Early administration of

482

significantly reduce symptoms, minimize time

484

admissions.
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485

Benzodiazepines may relieve nausea and

486

vomiting in patients with CHS. In one case

488

ondansetron and morphine, and could not

490

providers administered an IV dose of

492

minutes.14 Lorazepam enabled the patient to

487

study, a patient with CHS did not respond to

489

tolerate taking anything by mouth. The

491

lorazepam and his symptoms improved within

493

advance to a regular diet.14

495

CONCLUSION

497

cannabis more accessible, CHS will likely

499

warranted to assess trends in the diagnosis

501

Moreover, with the increasing popularity of

503

needed to improve drug toxicology screening.

505

screening, healthcare providers should

494
496

With national trends in legislation making

498

become increasingly common. More research is

500

and acute management of this condition.

502

synthetic cannabis, additional studies are

504

Because of the lack of synthetic cannabis

506

remain suspicious of CHS in patients with

Document18 07/24/19- 24

507

negative drug screening results. Once CHS is

509

helping affected patients and making them

508

identified, education serves as the key to

510

accountable for their own health.

512

REFERENCES

514

JC. Cannabinoid hyperemesis: cyclical

516

cannabis abuse. Gut. 2004;53:1566-1570.

518

2. Centers for Disease Control and

520

www.cdc.gov/nchs/data/hus/hus14.pdf#055.

522

text about updating this reference and the

524

reference from NIH/NIDA added at end of

511
513

1. Allen JH, de Moore GM, Heddle R, Twartz

515

hyperemesis in association with chronic

517
519

Prevention. Health, United States 2014.

521

Accessed January 19, 2019. [[AU: see note in

523

stats from it.] RESPONSE: Done. Additional

525

reference list]

527

3. Simonetto DA, Oxentenko AS, Herman ML,

526
528

Szostek JH. Cannabinoid hyperemesis: a case

Document18 07/24/19- 25

529

series of 98 patients. Mayo Clinic Proc.

530

2012;87(2):114-119.

532

4. Ukaigwe A, Karmacharya P, Donato A. A gut

534

hyperemesis syndrome due to K2, a synthetic

531
533

gone to pot: a case of cannabinoid

535

cannabinoid. Case Rep Emerg Med. 2014:1-3.

537

5. Kim HS, Anderson JD, Saghafi O, et al.

539

marijuana liberalization in Colorado. Acad

536
538

Cyclic vomiting presentations following

540

Emerg Med. 2015;22(6):694-699.

542

6. Soriano-Co M, Batke M, Cappell MS. The

544

by persistent nausea and vomiting, abdominal

546

chronic marijuana use: a report of eight

548

2010;55:3113-3119.

541
543

cannabis hyperemesis syndrome characterized

545

pain, and compulsive bathing associated with

547

cases in the United States. Dig Dis Sci.

549

Document18 07/24/19- 26

550

7. Patterson DA, Smith E, Monahan M, et al.

552

bathing: a case series and paradoxical

554

Fam Med. 2010;23(6):790-793.

556

8. Wallace EA, Andrews SE, Garmany CL,

558

literature review and proposed diagnosis and

560

2011;104(9):659-664.

562

9. Habboushe J, Sedor J. Cannabinoid

564

sequela of hyperemesis syndrome. Am J Emerg

551

Cannabinoid hyperemesis and compulsive

553

pathophysiological explanation. J Am Board

555
557

Jelley MJ. Cannabinoid hyperemesis syndrome:

559

treatment algorithm. South Med J.

561
563

hyperemesis acute renal failure: a common

565

Med. 2014;32(6):690-691.

567

10. Argamany JR, Reveles KR, Duhon B. Novel

569

resulting in rhabdomyolysis and acute renal

571

2.

566
568

case of synthetic cannabinoid hyperemesis

570

failure. Am J Emerg Med. 2016:34(4):765.e1-

Document18 07/24/19- 27

572
573

11. Alaniz VI, Liss J, Metz TD, Stickrath E.

575

refractory nausea and vomiting in pregnancy.

574

Cannabinoid hyperemesis syndrome: a cause of

576

Obstet Gynecol. 2015;125(6):1484-1486.

578

12. McClure EA, Sonne SC, Winhusen T, et al.

580

acetylcysteine treatment (ACCENT): design

582

randomized controlled study in the National

584

Network. Contemp Clin Trials.

577
579

Achieving cannabis cessation--evaluating N-

581

and implementation of a multi-site,

583

Institute on Drug Abuse Clinical Trials

585

2014;39(2):211-223.

587

13. Hickey JL, Mycyk MB. Haloperidol for

589

syndrome. Am J Emerg Med.

586
588

treatment of cannabinoid hyperemesis

590

2013;31(6):1003.e5-1003.e6.

592

14. Cox B, Chhabra A, Adler M, et al.

591
593

Cannabinoid hyperemesis syndrome: case

Document18 07/24/19- 28

594

report of a paradoxical reaction with heavy

596

2012;2012:757696.

597
598

[Internal Note: ADDITIONAL REFERENCES]

599
600

National Institutes of Health, National

602

the scope of marijuana use in the United

604

https://www.drugabuse.gov/publications/resea

606

use-in-united-states. Accessed January 19,

595

marijuana use. Case Rep Med.

601

Institute on Drug Abuse (NIH/NIDA). What is

603

States? June 2018. Available at

605

rch-reports/marijuana/what-scope-marijuana-

607

2019

609

Carliner H, Mauro PM, Brown QL, Shmulewitz

611

Martins SS, Carliner G, Hasin DS. The

613

prevalence in the U.S. during a period of

608
610

D, Rahim-Juwel R, Sarvet AL, Wall MM,

612

widening gender gap in marijuana use

614

economic change, 2002-2014. Drug Alcohol

Document18 07/24/19- 29

615

Depend. 2017;170:51-58. doi:

616

10.1016/j.drugalcdep.2016.10.042.

618

Governing. State Marijuana Laws in 2018 Map.

620

data/safety-justice/state-marijuana-laws-

622

January 19, 2019.

624

Galli JA, Sawaya RA, Friedenberg FK.

626

Abuse Rev. 2011;4(4):241-249.

617
619

Available at www.governing.com/gov-

621

map-medical-recreational.html. Accessed

623
625
627
628
629
630
631

Cannabinoid hyperemesis syndrome. Curr Drug

